TP53 and colorectal carcinoma: In this analysis, we identified APC, KRAS, NRAS and p53 to be mutated in both MSH2/MLH1-mutant CRCs (predicted MSI-H) and the non-MSI-H CRC samples with no statistically significant difference: APC (88.11% vs. 71.39%), KRAS (42.57% vs. 39.62%), p53 (62.37% vs. 58.